MX2023008168A - Complejos peptidicos biciclicos heterotandem. - Google Patents

Complejos peptidicos biciclicos heterotandem.

Info

Publication number
MX2023008168A
MX2023008168A MX2023008168A MX2023008168A MX2023008168A MX 2023008168 A MX2023008168 A MX 2023008168A MX 2023008168 A MX2023008168 A MX 2023008168A MX 2023008168 A MX2023008168 A MX 2023008168A MX 2023008168 A MX2023008168 A MX 2023008168A
Authority
MX
Mexico
Prior art keywords
peptide complexes
bicyclic peptide
heterotandem bicyclic
heterotandem
present
Prior art date
Application number
MX2023008168A
Other languages
English (en)
Inventor
Gemma Mudd
Liuhong Chen
Kevin Mcdonnell
Nicholas KEEN
Phil Brandish
Katie Gaynor
Fay Dufort
Chris Leitheiser
Liz Repash
Sandra Uhlenbroich
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2023008168A publication Critical patent/MX2023008168A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a complejos peptídicos bicíclicos heterotándem que comprenden un primer ligando peptídico, que se une a un componente presente en una célula cancerosa, conjugado a través de un conector a uno o más segundos ligandos peptídicos, que se unen a uno o más componentes presentes en una célula asesina natural (NK); la invención también se refiere al uso de dichos complejos peptídicos bicíclicos heterotándem para prevenir, suprimir o tratar el cáncer.
MX2023008168A 2021-01-08 2022-01-10 Complejos peptidicos biciclicos heterotandem. MX2023008168A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135273P 2021-01-08 2021-01-08
US202163262599P 2021-10-15 2021-10-15
PCT/GB2022/050044 WO2022148975A1 (en) 2021-01-08 2022-01-10 Heterotandem bicyclic peptide complexes

Publications (1)

Publication Number Publication Date
MX2023008168A true MX2023008168A (es) 2023-07-25

Family

ID=80050628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008168A MX2023008168A (es) 2021-01-08 2022-01-10 Complejos peptidicos biciclicos heterotandem.

Country Status (9)

Country Link
US (1) US20240197897A1 (es)
EP (1) EP4274844A1 (es)
JP (1) JP2024503632A (es)
KR (1) KR20230141794A (es)
AU (1) AU2022206577A1 (es)
CA (1) CA3206529A1 (es)
IL (1) IL304241A (es)
MX (1) MX2023008168A (es)
WO (1) WO2022148975A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529427A (ja) 2017-08-04 2020-10-08 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP5372380B2 (ja) 2005-01-24 2013-12-18 ペプスキャン システムズ ベー．フェー． 結合化合物、免疫原性化合物およびペプチド模倣体
EP2653544A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
DK3215518T3 (da) 2014-10-29 2021-05-25 Bicyclerd Ltd Bicykliske peptidligander, der er specifikke for mt1-mmp
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019136442A1 (en) * 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
JP7551500B2 (ja) * 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
US20200109195A1 (en) * 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
BR112021011340A2 (pt) * 2018-12-13 2021-09-08 Bicycletx Limited Ligantes de peptídeo bicíclico específicos para mt1-mmp
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3897851A2 (en) * 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
JP2022514687A (ja) 2018-12-21 2022-02-14 バイスクルアールディー・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
BR112021022315A2 (pt) * 2019-05-09 2021-12-28 Bicycletx Ltd Ligantes de peptídeo bicíclicos específicos para ox40

Also Published As

Publication number Publication date
EP4274844A1 (en) 2023-11-15
KR20230141794A (ko) 2023-10-10
US20240197897A1 (en) 2024-06-20
AU2022206577A9 (en) 2024-05-09
IL304241A (en) 2023-09-01
AU2022206577A1 (en) 2023-08-24
JP2024503632A (ja) 2024-01-26
CA3206529A1 (en) 2022-07-14
WO2022148975A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MX2022001290A (es) Complejos de peptido biciclico en heterotandem.
MX2020010444A (es) Complejos de péptidos bicíclicos en heterotándem.
MX2023008168A (es) Complejos peptidicos biciclicos heterotandem.
PH12019500270A1 (en) Combination therapy for cancer
TW200706682A (en) Unsymmetrical ligand sources, reduced symmetry metal-containing compounds, and systems and methods including same
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
EA202091714A1 (ru) Комбинированная терапия cd70
MY197562A (en) Cd3 binding polypeptides
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
MX2018011939A (es) Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
AU2018278730A1 (en) A novel anti-c-Met antibody and use thereof
IL179904A0 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MX2021014472A (es) Moleculas de union a tigit y pd-1/tigit.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022002524A (es) Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer.
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
WO2023018722A3 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
MX2020009743A (es) Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2023023345A3 (en) Methods of using activin receptor type ii signaling inhibitors
MX2021012386A (es) Proteínas de union triespecíficas, métodos y usos de las mismas.
MX2022001882A (es) Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
MX2022008061A (es) Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento del miembro 8 de la superfamilia de inmunoglobulina(igsf8).
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
AR119512A1 (es) Complejo de péptidos bicíclicos hetero-tándem